Poseida Therapeutics (STU:2RZ) Ending Cash Position : €49.03 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Ending Cash Position?

Poseida Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was €49.03 Mil.

Poseida Therapeutics's quarterly Ending Cash Position increased from Sep. 2023 (€23.90 Mil) to Dec. 2023 (€40.78 Mil) and increased from Dec. 2023 (€40.78 Mil) to Mar. 2024 (€49.03 Mil).

Poseida Therapeutics's annual Ending Cash Position declined from Dec. 2021 (€182.60 Mil) to Dec. 2022 (€76.82 Mil) and declined from Dec. 2022 (€76.82 Mil) to Dec. 2023 (€40.78 Mil).

Poseida Therapeutics Ending Cash Position Historical Data

The historical data trend for Poseida Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Ending Cash Position Chart

Poseida Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

79.01

69.02

182.60

76.82

40.78

Poseida Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															37.49	46.07	23.90	40.78	49.03

Poseida Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Poseida Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	74.624	+	-33.843
	=	40.78

Poseida Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	40.914	+	8.119
	=	49.03

Poseida Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics (STU:2RZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

PSTX:USA

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Poseida Therapeutics (STU:2RZ) Headlines

No Headlines